SXI Life Sciences
7.772,36
PKT
-3,32
PKT
-0,04
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Leider sind zu diesem Wert keine aktuellen Kursdaten verfügbar, die Stammdaten finden Sie im unteren Seitenbereich.
Analysen zu SXI Life Sciences-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 13.06.16 | Roche buy | Deutsche Bank AG | |
| 07.06.16 | Roche overweight | JP Morgan Chase & Co. | |
| 06.06.16 | Roche Hold | HSBC | |
| 31.05.16 | Roche overweight | Morgan Stanley | |
| 31.05.16 | Novartis Underweight | Morgan Stanley | |
| 31.05.16 | Roche overweight | JP Morgan Chase & Co. | |
| 31.05.16 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 26.05.16 | Novartis overweight | JP Morgan Chase & Co. | |
| 23.05.16 | Novartis overweight | JP Morgan Chase & Co. | |
| 23.05.16 | Novartis Neutral | Citigroup Corp. | |
| 19.05.16 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 19.05.16 | Novartis overweight | JP Morgan Chase & Co. | |
| 19.05.16 | Roche overweight | JP Morgan Chase & Co. | |
| 18.05.16 | Novartis Underweight | Morgan Stanley | |
| 18.05.16 | Novartis Neutral | Citigroup Corp. | |
| 11.05.16 | Novartis buy | Jefferies & Company Inc. | |
| 11.05.16 | Roche buy | Jefferies & Company Inc. | |
| 09.05.16 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 28.04.16 | Novartis Neutral | UBS AG | |
| 26.04.16 | Novartis Outperform | Bernstein Research | |
| 26.04.16 | Roche Outperform | Bernstein Research | |
| 26.04.16 | Novartis buy | HSBC | |
| 26.04.16 | Novartis Neutral | BNP PARIBAS | |
| 25.04.16 | Novartis overweight | JP Morgan Chase & Co. | |
| 22.04.16 | Novartis Underweight | Morgan Stanley | |
| 22.04.16 | Novartis Equal weight | Barclays Capital | |
| 21.04.16 | Novartis buy | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 20.04.16 | Roche overweight | Morgan Stanley | |
| 20.04.16 | Roche overweight | JP Morgan Chase & Co. | |
| 20.04.16 | Novartis overweight | JP Morgan Chase & Co. | |
| 19.04.16 | Novartis Neutral | Goldman Sachs Group Inc. | |
| 18.04.16 | Roche buy | UBS AG | |
| 15.04.16 | Novartis Neutral | UBS AG | |
| 14.04.16 | Novartis Underweight | Barclays Capital | |
| 13.04.16 | Novartis overweight | JP Morgan Chase & Co. | |
| 12.04.16 | Roche overweight | JP Morgan Chase & Co. | |
| 12.04.16 | Novartis Underweight | Morgan Stanley | |
| 12.04.16 | Roche Conviction Buy | Goldman Sachs Group Inc. | |
| 06.04.16 | Novartis Hold | Société Générale Group S.A. (SG) | |
| 05.04.16 | Roche overweight | Morgan Stanley |